currently recruiting - clinical trials for adrenal disease
"Those of us with adrenal disease know the importance of having new treatments that will give us an opportunity to have the best quality of life with improved medical options. Participation in clinical trials can help accelerate the development of new treatments and address our community's unmet medical needs."
--Lori Engler, NADF Co-President
See details on active clinical trials on our website: https://www.nadf.us/clinical-trials.html. You may find information about these and other studies at https://clinicaltrials.gov/
UPDATED DIAGNOSTIC CORTSOL VALUES FOR ADRENAL INSUFFICIENCY
The purpose of this study is to determine the cortisol levels that most accurately diagnose a patient with adrenal insufficiency, a condition in which cortisol levels are too low for daily living.
- Sponsor: Montefiore Medical Center
- Contact person: Smita B. Abraham, MD; email: firstname.lastname@example.org
- Who should consider participating: If you are a male or a female, 18 years or older, consider participation to help determine the appropriate level of cortisol in healthy individuals to allow a more accurate diagnosis of people with adrenal insufficiency.
SPI-62 as a treatment for hypercortisolism related to a benign adrenal tumor (ACSPIRE)
This study evaluates the efficacy, safety, and pharmacological effect of SPI-62 in subjects with hypercortisolism related to a benign adrenal tumor.
- Sponsor: Sparrow Pharmaceuticals
- Contact Person: Frank Czerwiec, MD; email email@example.com
- Who should consider participating: This study is designed for people with Endogenous Cushing’s Syndrome (Cushing’s) seeking new treatments for cortisol excess. SPI-62 targets a major source of intracellular cortisol, and it may be more effective at alleviating symptoms while simultaneously offering a stronger safety and tolerability profile.
A Study of Gene Therapy for Classic Congenital Adrenal Hyperplasia (CAH)
- This study is designed to evaluate the safety, tolerability, and efficacy of AAV5-based BBP-631 in adult participants diagnosed with classic congenital adrenal hyperplasia.
- Sponsor: Adrenas Therapeutics
- Contact Person: Patient Advocacy; email ClinicalTrials@AdrenasTx.com
- Who should consider participation: If you are an adult living with classic CAH due to 21-hydroxylase deficiency and interested in gene therapy treatment that may correct hormone imbalances.
SPRUCE BIOSCIENCES NOW ENROLLING CAHMELIA CLINICAL TRIAL
This study is designed to evaluate the efficacy of tildacerfont on disease control or reduction of glucocorticoid use in pediatric subjects with classic CAH.
- Sponsor: Spruce Biosciences
- Study Contact: Clinical Trials phone number: 415-655-4169: CAHptain@sprucebiosciences.com
- Who should consider participating: Children and teenagers, age 2-17, diagnosed with CAH due to 21-hydroxylase deficiency and/or elevated 17-hydroxyprogesterone requiring ongoing glucocorticoid replacement.
NADF does not endorse any product, merely informing our members about a new clinical trial.